Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 6/20 | 0.51 |
| ▸ | CA1 known ✓ | P00915 | 6/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.51 |
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1693977 | 1.00 | TDP1 (0.53) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL26603598 | 1.00 | TDP1 (0.53) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL30062309 | 1.00 | TDP1 (0.53) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18780618 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL4455260 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL6033324 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL179912 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL14417100 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL12569327 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL3622089 | 0.92 | TDP1 (0.54) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20220110870-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| US-8846053-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | SDG, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | CA12 3441/4885CA1 2920/4885CA2 2092/4885 |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | CA12 3345/4885CA1 4092/4885CA2 4346/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | CA12 3221/4885CA1 3267/4885CA2 698/4885 |
| US-20220110870-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | CA12 2944/4885CA1 2697/4885CA2 3633/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | CA12 3441/4885CA1 2920/4885CA2 2092/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | CA12 1226/4885CA1 2890/4885CA2 3952/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | CA12 3245/4885CA1 3115/4885CA2 2034/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | IAPP, IDE, INSR | CA12 4358/4885CA1 4861/4885CA2 3962/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | CA12 2944/4885CA1 2697/4885CA2 3633/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | CA12 2944/4885CA1 2697/4885CA2 3633/4885 |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, LIPC, FABP6 | CA12 1226/4885CA1 2890/4885CA2 3952/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | CA12 3452/4885CA1 2966/4885CA2 2040/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | CA12 1226/4885CA1 2890/4885CA2 3952/4885 |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | CA12 2944/4885CA1 2697/4885CA2 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.